ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly.
… ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration Partnership focused on … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Axiomer has the potential to restore precise levels of the …
… ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 LEIDEN, … transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today announced a …
… ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 Platform … transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted …
… ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event Initial … during which the Company will showcase its proprietary Axiomer RNA-editing technology platform, detail the pipeline, …
